Is Lorlatinib available in China now?

In April 2022, Lolatinib (Lorlatinib) tablets were approved by the State Food and Drug Administration and launched in China. The single drug is suitable for patients with anaplastic lymphoma kinase (ALK)-positive tumors. For the treatment of patients with locally advanced or metastatic non-small cell lung cancer, its main mechanism of action is to prevent abnormal signaling by inhibiting the activity of ALK (tyrosine kinase) and ROS1 proteins, thereby inhibiting the growth and spread of cancer cells. Lorlatinib has been included in medical insurance since its launch. However, due to its short time on the market, reimbursement may only be limited to patients who meet the indications. The price of the original drug is relatively high, about 10,000 to 20,000 yuan.